The mercuriosity method

Communication. Congruence. Visibility.
For MedTech startup founders.

Who need investors, surgeons, hospital buyers and regulators to understand the same truth, while the evidence is still developing.

New edition every other week. Unsubscribe anytime.

Mercuriosity mark, liquid mercury merging

The problem

Most early MedTech companies stall on incongruence.

Strong ideas, real clinical relevance, founders who know their technology. And still, slow traction. Four patterns show up almost every time.

01

Communication outruns the evidence.

Claims sound stronger than the actual proof stage can support.

02

One story for everyone.

Investors, surgeons and hospital buyers get the same materials, though they need different versions of the same truth.

03

Visibility starts too late.

Founders wait until approval to become visible, while trust should already be compounding.

04

Nothing built from the same narrative.

Deck, website, regulatory file and founder profile were created at different moments, with different assumptions.

The three disciplines

Three disciplines that work together.

The trio is the methodology. Audits, scorecards and advisories all take one of the three as a prefix.

Discipline 01

Communication.

What you say, and how you say it.

TextVoiceVisual identityClaim discipline
Discipline 02

Congruence.

Whether all your expressions tell one coherent story.

DeckWebsiteRegulatory fileFounder profile
Discipline 03

Visibility.

Whether the right people see and recognize you.

ChannelsPresenceFounder signalPeer trust

For whom

Who this is for.

Built for surgeon-inventors and early MedTech founders building surgical devices the market has not discovered yet.

My deepest experience is in orthopedics and neurosurgery, where I have helped build companies from concept to acquisition. If your device sits in those fields, you will find the most direct relevance.

  • Surgeon-inventors with a real clinical problem and a device idea
  • Early MedTech startups in orthopedics or neurosurgery, TRL 3–6
  • Pre-clinical or clinical design stage, pre-CE or pre-Notified Body sign-off
  • Medical inventors pre-incorporation, needing credibility for investors
Adjacent fit

Founders in adjacent surgical specialties recognize the same patterns. The free tools are open to them too. Mercuriosity's deepest advisory fit stays with implantable devices in orthopedics and neurosurgery.

Explore the tools

Who I am

Built from inside MedTech.

Mercuriosity is founded by Nancy Lamerigts, MD PhD, a physician-entrepreneur with twenty years in spine, hospital reality and surgeon relationships through InSpine.

She designed and marketed implants for EIT, now sold by DePuy Synthes under Conduit, and applies the same operating logic across Cresco Spine and Atraxon Biotech.

MD · PhD
Physician-entrepreneur
20 yrs
In spine
Track Record
R&D · Building · Exit
4
Companies · InSpine, EIT, Cresco, Atraxon
Nancy Lamerigts, MD PhD, founder of Mercuriosity
Nancy Lamerigts
Founder · MD PhD
The Operating Table
Every other week · for surgeon-inventors
Sister publication

The ideas come first.

The Operating Table is the publication by Nancy Lamerigts. Frameworks, teardowns, signal analysis and case breakdowns for pre-market surgical device founders. Every edition serves Communication, Congruence or Visibility.

Read the newsletter

Choose your starting point

Three routes. Pick whichever fits your week.

Route 01 · Read

Read The Operating Table.

Start with the frameworks before you change anything. Free, and the fastest way to test whether this voice is for you.

Open the newsletter
Route 02 · Diagnose

Take the Congruence Scan.

A short diagnostic on where deck, website, regulatory file and founder profile drift apart. You see the gap before anyone else points it out.

Take the scan
Route 03 · Talk

Founder Clarity Call.

A thirty-minute consultation. Bring your Congruence Scan outcome, deck, website or regulatory narrative. You leave with the most concrete observation, whether you work with us or not.

Request a call